By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alder Biopharmaceuticals Inc. 

Corporate Headquarters
11804 North Creek Parkway South
Bothell  Washington  98011  U.S.A.
Phone: 425-205-2900 Fax: 425-205-2901

Alder is revolutionizing the way antibody therapies are identified, selected, developed and produced. Our proprietary technologies make great strides possible in the field of antibody therapeutics, dramatically accelerating the way pharmaceutical and biotechnology companies bring new therapies to market.

Alder has developed two unique antibody technologies that together increase antibody potency, drastically accelerate production cycles, and lower overall production costs. These unique technologies--the Antibody Selection (ABS) System and our novel Mab Xpress® Antibody Production System--are cornerstones of our company and catalysts for change in the pharmaceutical industry.

Proprietary technology and a vision for the future of antibody therapeutics make Alder the ideal partner for leading pharmaceutical and biotechnology companies. Since inception, we have actively pursued strategic alliances with commercial and academic partners who share our goal of reducing the time and cost of developing superior antibodies for a range of unmet medical needs.

At Alder we seek talented contributors who thrive in a high-energy team environment and want to make a real and lasting impact in the field of antibody therapeutics. Alder teams are creative, collaborative, open, committed--and central to the success of this company and its mission. If this is the kind of company you want to work for, we want to hear from you.

Key Statistics

Ownership: Private

Web Site: Alder Biopharmaceuticals Inc.


Company News
Alder Biopharmaceuticals Inc. To Host Conference Call To Discuss Third Quarter 2014 Financial And Operating Results 10/24/2014 10:18:01 AM
Data From Alder Biopharmaceuticals Inc.' Proof-Of-Concept Clinical Trial Of ALD403 Published In Lancet Neurology Demonstrates ALD403 Effective In The Preventive Treatment Of Migraine 10/6/2014 7:32:40 AM
Bristol-Myers Squibb Company (BMY) Gives Back Rights To Alder Biopharmaceuticals Inc.'s Promising Arthritis Drug Clazakizumab 9/2/2014 8:12:26 AM
Alder Biopharmaceuticals Inc. Reports Second Quarter 2014 Financial And Operating Results 8/5/2014 3:19:33 PM
Alder Biopharmaceuticals Inc. To Host Conference Call To Discuss Second Quarter 2014 Financial And Operating Results 7/29/2014 8:53:24 AM
Alder Biopharmaceuticals Inc. Added to Russell 3000® Index 6/27/2014 8:43:04 AM
Alder Biopharmaceuticals Inc. Release: Data From Proof-Of-Concept Clinical Trial Of ALD403, A Monoclonal Antibody Against CGRP For The Prevention Of Migraine, To Be Presented At 56th Annual Scientific Meeting Of The American Headache Society 6/26/2014 7:22:03 AM
Alder Biopharmaceuticals Inc. Reports First Quarter 2014 Financial Results 6/19/2014 8:16:31 AM
Alder Biopharmaceuticals Inc. To Present At Two Conferences In June 6/11/2014 6:38:12 AM
Biotech IPO Slump Continues as Alder Biopharmaceuticals Inc. Prices Below Range 5/8/2014 8:50:27 AM